Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc., a Canadian company specializing in light-activated antimicrobial treatments, has announced a C$5 million private placement financing to issue new common shares, aimed at bolstering working capital and supporting commercial growth. The investment, anticipated to close by November 8, 2024, will also complement the company’s recent distribution partnership with Mölnlycke Health Care, enhancing expected sales growth.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
